1-7 of 7
Yun Su
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc
Journal: Blood
Blood (2017) 130 (Supplement 1): 2558.
https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558
Published: 2017
Journal Articles

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices

Thomas W. LeBlanc, MD MA, Azah Borham, PharmD, Yun Su, MD MPH, MS, Karin Chun Hayes, Russel Fielding, Michael Benigno, MA, Joseph C. Cappelleri, PhD MPH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1328.
https://doi.org/10.1182/blood.V130.Suppl_1.1328.1328
Published: 2017
Journal Articles

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, MD, Yun Su, MD MPH, Elias J. Jabbour, MD, Helen Bhattacharyya, PhD, Eric Yan, PhD, Mark Shapiro, MD PhD, Joseph C. Cappelleri, PhD MPH, MS, David I. Marks, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1599.
https://doi.org/10.1182/blood.V128.22.1599.1599
Published: 2016
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD
Journal: Blood
Blood (2016) 128 (22): 3095.
https://doi.org/10.1182/blood.V128.22.3095.3095
Published: 2016
Journal Articles

The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Stuart L. Goldberg, MD, Yun Su, MD MPH, MS, Candace Gunnarsson, EdD, MA, William D Irish, PhD, Michael Ryan, MS, Mabel Woloj, MD, Roxanne Ferdinand, MBBS MRCP MFPM, Mark Shapiro, MD
Journal: Blood
Blood (2015) 126 (23): 2797.
https://doi.org/10.1182/blood.V126.23.2797.2797
Published: 2015
Journal Articles

Burden Of Illness and Treatment Patterns For Patients With Multiple Myeloma In a US Integrated Healthcare System

Nazia Rashid, PharmD, MS, Yi-Lin Wu, MS, Yun Su, MD, Elizabeth Fong, PharmD
Journal: Blood
Blood (2013) 122 (21): 3228.
https://doi.org/10.1182/blood.V122.21.3228.3228
Published: 2013
Journal Articles

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Ravi Vij, MD, Mehdi M. Moezi, MD, Robin Foà, MD, Gordon Cook, MD, PhD, Antonio Palumbo, MD, Hakan Kaya, MD, Brian Durie, MD, David Cella, PhD, Lieven Annemans, PhD, Yun Su, MD, Pralay Mukhopadhyay, PhD, Trong K. Le, MPH, MS, Maria Teresa Petrucci, MD
Journal: Blood
Blood (2013) 122 (21): 1964.
https://doi.org/10.1182/blood.V122.21.1964.1964
Published: 2013